Full Press Release Details
Annual General Meeting
ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034
Notice: Forward Looking Statements
the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche B rse:YP1B.DE). These slides have been prepared as a presentation aid only and the information they contain may require
further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of
information. Please refer to the Company s website and/or the Company s filings to the ASX and SEC for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to
the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations
and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed s control. Important factors that could cause actual results to differ materially from assumptions or expectations
expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed s current intentions, plans, expectations and beliefs about the future, you are urged
to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to
sell or a solicitation of an offer to
buy or sell shares in any jurisdiction.
Cancer Immunotherapy - Way of the future
Immunotherapy the beginning of
Immunotherapies -$35bn
potential/ annum. Will likely become the treatment backbone in up to 60% of cancers in the next 10 years
Andrew S Baum Citi Equities Research 22 May 2013
Prima in Prime Position!
Immunotherapy rapidly
growing & evolving industry
Multiple approaches with multiple products
diversified portfolio
Leading edge research & IP generating new
Strong commercial partnerships with potential
Strong research team and advisory boards
Transformational Acquisition
Prima s Potential in Multiple Approaches
Cellular therapy, Antibody therapy
Turn on the immune system
Immune checkpoint agents,
Cytokine therapy, Antibody therapy
Partner Preclinical Phase I Phase IIa
Phase IIb Phase III Indication
Cancer + Chemotherapy
Portfolio of advanced products
Strong partnerships with big pharma companies
(GSK, Novartis, Eddingpharm, Neopharm)
Partly no development costs = lower risk
revenue potential: milestones are near-
mid- and long-term oriented
Global grant options in Australia, Germany and
Mission: Emerging leader in
Expanded Operational Management Team
Toloczyki, PhD, Director Quality Assurance
25+ years experience in the pharmaceutical, biotechnological
and medical device industries and strong background in quality assurance processes by holding different positions with responsibility for development, testing, production and quality control
Frank Fliegert, PhD, Global Medical Director
8+ years experience in various R&D positions, held position as Vice President Clinical Development at
NOXXON, as Clinical Pharmacology Program Leader at Boehringer-Ingelheim and as Head of the Clinical
Pharmacology Unit at SynteractHCR
Buchholz, PhD, Global Director of Manufacturing
manages the manufacturing of CVac; prior he was a project
manager at the Fraunhofer IZI; before completed his PhD at the Centre for Regenerative Medicine at the University of Bath and has a degree in Biochemistry from the Free University in Berlin
Jeanine Ronniger, Global Project Director
15+ years of experiences in the pharmaceutical research industry to lead and support actual and future programs;
her scientific knowledge based on 11 years intensive care unit as registered nurse followed by further
educations on Business Administration, Consumer Health Care and Project Management
Larisa Chisholm, Business Development and Intellectual Property Manager
manages the intellectual property portfolio, worked at the Burnet Institute; has a Bachelor of Science
(Hons) majoring in Biochemistry and Genetics and a Master s Degree in Business Administration
Upcoming Catalysts in CY2015
clinical trial with IMP321
Continued development of phase I study with IMP731
Potential material milestone payments during 2015
Start of phase I study with IMP701
CVac: patient recruitment of CAN-004B and CAN-301,
Final OS readout of CAN-003
Achievement of regulatory milestones
for potential grants
FINANCIAL DATA FY2014
Key Financial Data of FY 2014
STATEMENT OF COMPREHENSIVE INCOME
30 June 2014 30 June 2013 30 June 2012
Research & development and
intellectual property
Corporate administrative expenses
Depreciation, loss on forex $ (446.360) $ (287.738) $ (3.047.092)
Loss before income tax expense
Loss after income tax expense for
Other Comprehensive Income
Cash burn rate has decreased over the last three FYs!
Cash position: last 4C: ~20m AUD
Total consideration up to approx.
US$18M in cash (US$10.8M upfront payment; 40% based
on milestones/retention)
US$3M in ordinary PRR shares
options and warrants (approx. US$7M in value)
partly dependent on milestones
Consideration in context:
Average upfront payment for licensing a single Phase II
oncology product is US$38M; average deal value is US$221M*
Attractive acquisition price
FY2014 CVac in review
Very Positive Interim Overall Survival Data:> 36Mo CVac vs
Clear Target Patient Population identified of 2nd remission
Observation continues
2nd remission EOC patients, enrolment ongoing (21 sites active) -> more sites will be activated
CVac in pancreatic cancer commencing Q4
Continuous optimisation for minimising